Patient Recruitment Feasibility Analysis

Eosinophilic Asthma
Eosinophilic Asthma  ·  Phase 3

NCT06750289  |  AstraZeneca  |  RECRUITING

This report maps the addressable patient population within reach of your site, the eligibility barriers that shape the funnel, and what a realistic recruitment campaign looks like from your geography.

View Full Analysis

Generated May 08, 2026   ·  Prepared for Paradigm Clinical Research

Executive Summary

Recruitment Outlook: Eosinophilic Asthma

Sponsor
AstraZeneca
Phase
Phase 3
Enrollment Target
400 patients
US Sites
34
Est. Completion
2027-11-03
Digital Outreach Potential
8/10
Meta reaches condition-relevant audiences with strong targeting potential. Google Search adds moderate secondary reach among active symptom searchers.
85,000
Est. addressable audience
Google — Moderate
Secondary channel
Patient Recruitment Complexity
5/10
An estimated 13% of respondents meet the full qualification criteria. At 35:1 leads per enrolled patient, expect complex-level screening overhead.
13%
Leads that qualify
35:1
Leads per patient
Key Considerations
Asthma is a highly reachable condition for digital advertising with strong patient motivation and self-identification. However, the specific requirement for medium-dose ICS-LABA therapy (not low, not high), combined with exacerbation history, eosinophil counts, and a demanding run-in period, significantly narrows the eligible pool from what appears to be a large addressable audience. This trial is feasible for digital recruitment but will require disciplined pre-screening and higher-than-average lead volumes to hit enrollment targets.
Above Average
Site geography rank among 34 sites for digital recruitment

Digital Outreach Analysis

Digital Outreach Potential

8/10
Primary Channel: both Meta and Google Search

Platform Reach Assessment

Meta (Facebook/Instagram)
Easy Difficulty — Broad Reach
AstraZeneca's own DTC campaigns for Fasenra create ad auction competition and may cause confusion between commercial and trial messaging
Google Search
Moderate Difficulty — High Search Demand
Google search demand for asthma-related queries is strong and year-round, with spikes during allergy and respiratory illness seasons. Terms like 'asthma clinical trial,' 'new asthma treatment,' and 'asthma not controlled' provide excellent intent signals for pre-qualified leads.

Recruitment Challenges

  • AstraZeneca's own DTC campaigns for Fasenra create ad auction competition and may cause confusion between commercial and trial messaging
  • Broad asthma audience targeting will attract many mild or well-controlled patients who do not meet the uncontrolled/exacerbation criteria, inflating cost per qualified lead
  • Adolescent inclusion (12-17) requires parental consent workflows and Meta restricts health-related ad delivery to minors, reducing reach for that sub-group

Recruitment Advantages

  • Asthma patients are highly motivated to seek new treatments, especially those experiencing frequent exacerbations, driving strong click-through and form completion rates
  • Google search campaigns can capture patients actively searching for alternatives after poor control on current inhalers, yielding higher-quality leads
  • Seasonal respiratory triggers (fall/winter) create natural urgency windows for campaign pushes with timely creative messaging

Competitive Landscape

Competing Trial Activity: Eosinophilic Asthma

No Competing Trials in Your Area
Our search found no other Eosinophilic Asthma trials actively recruiting within 50 miles of Modesto, CA.
Uncontested
50-mile radius
Modesto, CA
100%
Uncontested
patient pool
No other site is competing for the same eligible patients in your market. Every qualified lead your ads generate is yours alone.
Exclusive recruitment territory
~25%
Estimated CPL reduction vs. contested markets
No bid competition driving up ad costs or splitting patient attention
0
Competing studies seen by patients here
No recruitment fatigue. Your ads reach a fresh, uncontacted audience.

Enrollment Analysis

Patient Recruitment Complexity

Patient Population Size
~25M asthma; ~12–15M eosinophilic phenotype
Recruitment Difficulty
Complex
Leads That Qualify
13%
Est. Leads Per Patient
35:1
Patient Journey

From first click to enrolled patient

35
Leads
generated
12
Protocol
screened
1
Patient
enrolled
The Patient Enrollment Funnel

Projected figures based on protocol criteria and local population estimates.

LEADS GENERATED 35 ad responses REACH SCREENING 12 protocol qualified RANDOMIZED 1 enrolled patient
1 in 35
ad responses converts to an enrolled patient for this protocol
1 in 3
leads qualify for protocol screening
8%
of screened patients go on to randomize
$6,300–$11,200
Estimated cost per randomized patient
At $180–$320 CPL, the 35:1 lead ratio implies $6,300–$11,200 per randomized patient.
Estimated Time to Enrollment Target
10mo
16mo
10–16 months estimated to reach enrollment target

Population estimates based on U.S. Census ACS 5-Year Estimates.

Our Assessment

Eosinophilic Asthma Recruitment: Our Read for Paradigm Clinical Research

Eosinophilic Asthma has a viable digital recruitment path, with some complexity to plan around. The patient population is reachable, but the eligibility criteria will require careful qualification messaging. The right infrastructure and patient-facing language can generate qualified leads at scale.

Recruitment Challenges

What we'll need to work around

  • High screen-fail rate driven by the narrow medium-dose ICS-LABA window, which is difficult for patients to self-identify accurately in digital pre-screening
  • Competitive saturation in the eosinophilic asthma trial space, with multiple biologics recruiting from the same patient pool in overlapping geographies
  • Run-in period attrition (compliance + sustained ACQ threshold) will cause randomization losses even among otherwise eligible, consented patients
Recruitment Advantages

What works in your favor

  • Lower eosinophil threshold (150 vs. 300) compared to competing trials provides a broader eligible pool and can be messaged as a competitive advantage to sites
  • Florida-heavy site distribution aligns well with large, digitally active populations and year-round respiratory symptom burden
  • Dual-platform strategy (Meta for awareness, Google for intent capture) can build a robust lead funnel for a condition with strong search demand
What This Means for Your Study

Key implications

  • Digital outreach potential scores 8/10. Channel mix should be confirmed in scoping.
  • Enrollment complexity scores 5/10. Expect a tighter lead-to-screen conversion than average.
  • Budget planning should account for a longer optimization period relative to standard campaigns.
Indication Benchmark

Cost per patient is roughly 1.5-2.5x a baseline Phase 2/3 campaign, driven primarily by the specific medium-dose ICS-LABA requirement and multi-visit run-in period that inflate the leads-to-randomization ratio despite asthma's large prevalence base.

Our Recommended Approach

Our Recommended Approach for Eosinophilic Asthma Recruitment

Based on the analysis above, here is the specific approach we would build for Eosinophilic Asthma.

THE CREATIVE
Lead With Exacerbation Frustration, Not Clinical Jargon
Develop video and static creative centered on the emotional toll of repeated asthma flare-ups: missed work, ER visits, and the fear of the next episode. Use language like 'Had 2 or more asthma flare-ups this past year?' as a qualifying hook that doubles as an inclusion criterion filter. Avoid the term 'eosinophilic' in patient-facing creative since most patients do not know their phenotype.
THE PRE-SCREEN
Smart Questionnaire to Filter the Medium-Dose ICS-LABA Requirement Early
Build a 6-question pre-screening form that asks respondents to name their current inhaler (with visual aids showing common devices), estimate how many ER visits or steroid bursts they had in the past year, and confirm smoking status. Include a medication-matching algorithm that maps named inhalers to dose classifications, flagging medium-dose ICS-LABA candidates for priority site referral. This single step can reduce screen-fail rates by 30-40%.
THE SEASONAL PUSH
Time Campaign Surges to Fall and Winter Exacerbation Peaks
Allocate 40% of annual ad budget to September through February when respiratory infections and cold air triggers drive asthma exacerbation rates to their highest. During these windows, deploy urgency-driven creative referencing seasonal flare-ups and increase daily budgets by 50%. This aligns maximum ad spend with the period when patients are most symptomatic, most motivated, and most likely to meet the 2-exacerbation threshold.

The infrastructure is proven. The approach above is built specifically for this indication, this eligibility profile, and this market.

60+ patients randomized | 30+ indications served | $1,167 avg. cost per patient

Ready to Move Forward?

The Report Shows What's Possible. Let's Talk About Making It Happen.

We'll review your protocol in detail, map your site's patient access window given the local population and trial competition, and walk through what a campaign from us would look like for this specific study.

60+ Patients randomized
30+ Indications served
$1,167 Avg. cost per randomized patient (published engagements)
Reserve a Strategy Call

clinicalenroll.com  ·  This analysis is prepared for the recipient only. Report expires 28 days from generation.